This is a past event.
John W. Osborn, PhD
Professor of Integrative Biology and Physiology
Marvin and Hadassah Bacaner Endowed Chair in Cardiovascular Physiology, University of Minnesota School of Medicine
“RENAL NERVES, RENAL INFLAMMATION, AND HYPERTENSION: IS THERE A LINK?”
It is well established that hypertension is linked to overactivity of the sympathetic nervous system (SNS). Since the kidneys are known to play a key role in the regulation of blood volume and arterial pressure, there is a rich literature on the contribution of renal nerves to the pathology of hypertension. Although animal studies have clearly shown that renal denervation (RDNx) delays hypertension development, the mechanism of this treatment is unknown. Recent clinical trials in humans with drug resistant hypertension suggest that catheter based RDNx may be a novel anti-hypertensive therapy. Our lab is currently focused on understanding the basic mechanisms by which renal nerves cause hypertension, as well as the mechanisms mediating the antihypertensive response to RDNx. Recently, the hypothesis has emerged that neural-immune interactions play a key role in the pathogenesis of hypertension. We are currently combing whole animal integrative physiology, with electrophysiological, and immunological studies, to understand how renal nerves, renal inflammation, and hypertension are linked.
BIOGRAPH: Dr. John Osborn received his Ph.D. in 1986 in physiology from the Medical College of Wisconsin where he studied the neural-cardiovascular actions of vasopressin. He then went to Johns Hopkins School of Medicine for a post-doctoral fellowship in Biomedical Engineering where he focused on spinal level control of the sympathetic nervous system. In 1988 Dr. Osborn took a faculty position at the University of Minnesota where he currently holds the Marvin and Hadassah Bacaner Endowed Chair in Cardiovascular Physiology. Dr. Osborn has studied the relationship between sympathetic nervous system activity and hypertension throughout his career. His earlier studies focused on central nervous system pathways and hypertension. More recently he has shifted his focus to understanding the role of organ specific sympathetic pathways in the pathogenesis of cardiometabolic disease with the long term goal of developing device based neuromodulation therapies. Dr. Osborn is the founder and Director of the University of Minnesota Autonomic Neuromodulation Collaborative which consists of 30+ faculty in basic and clinical research. His research has been continuously funded by the National Institutes of Health for the past 30 years.
For more information, visit: http://osbornjw.wixsite.com/lab-website